References
- Pershing Square, Valeant and Allergan Settle Pending Litigation Before the Delaware Court of Chancery. www.valeant.com/Portals/25/PDF/09162014_settlement.pdf.
- Allergan comments on Pershing Square‘s delivery of additional requests from stockholders owning 1.5% of Allergan's shares. http://agn.client.sharehoder.com/releasedetail.cfm?ReleaseID=870493.
- Allergan Board of Directors issues statement. http://agn.client.sharehoder.com/releasedetail.cfm?ReleaseID=873431.
- Allergan issues statement regarding recent Valeant correspondence http://agn.client.sharehoder.com/releasedetail.cfm?ReleaseID=872562.
- Allergan provides update on written requests from Pershing Square regarding special meeting of stockholders. http://agn.client.sharehoder.com/releasedetail.cfm?ReleaseID=869268.
- Pfizer completes acquisition of InnoPharma. www.pfizer.com/news/press-release/press-releasedetail/pfizer_completes_acquisiiton_of_innopharma.
- Pfizer to acquire InnoPharma, Inc. http://innopharmainc.com/?p=642.
- Roche purchases shares in tender offer for InterMune, Inc. www.roche.com/media/media_releases/med-cor-2014–09–29b.htm.
- Roche purchases shares in tender offer for InterMune, Inc. http://investor.intermune.com/phoenix.zhtml?c=100067&p=irol-newsArticle_print&ID=1971606&highlight=.
- OnCore Biopharma licenses second-generation cyclophilin inhibitors from NeuroVive for the treatment of chronic HBV infection. www.oncorebiopharma.com/news.
- Acorda Therapeutics to acquire Civitas Therapeutics. http://ir.acorda.com/investors/investor-news/investor-news-details/2014/Acorda-Therapeutics-to-Acquire-Civitas-Therapetics/default.aspx?print=1.
- Endo delivers a proposal to acquire Auxilium Pharmaceuticals for $28.10 per share in cash and stock. http://phx.corproate-ir.net/phoenix.zhtml?c=231492&p=irol-newsArticle_print&ID=1968681.
- Auxilium provides transaction update. http://ir.auxilum.com/phoenix.zhtml?c=142125&p=irol=newsArticle_print&ID=1969837.
- Endo International comments on Auxilium Pharmaceutical's rejection of its acquisition proposal http://phx.corporate-ir.net/phoenix.zhtml?c=231492&p-irol-newsArticle_print&ID=1969996.
- Sun Pharma and Merck Co. Inc enter into licensing agreement for tildrakizumab. www.mercknewsroom.com/news-release/corporate-news/sun-pharma-and-merck-co-inc-enter-licensing-agreement-tildrakizumab.
- Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab. www.sunpharma.com/press-releases.
- Pfizer and Kyowa Hako Kirin to collaborate on immuno oncology combination study. www.pfizer.com/news/pres-release/pres-release-detail/pfizer_and_kyowa_hako_kirin_to_collaborate_on_immuno_oncology_combination_study.
- Pfizer and Kyowa Hako Kirin to collaborate on immuno oncology combination study. www.kyowa-kirin.com/news_releases/2014/pdf/e20140930_01.pdf.
- Merck Serono and Sutro Biopharma to Partner on Development of Antibody Drug Conjugates. www.merckgroup.com/en/media/extNewsDetail.html?newsld=3FD754235D1A99A3C1257D550080E08&newsType=1.
- Merck Serono and Sutro Biopharma to Partner on Development of Antibody Drug Conjugates. www.sutrobio.com/merck.
- Infinity and AbbVie Announce Global Strategic Collaboration to Develop and Commercialize Duvelisib (IPI-145) In Oncology. http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1963180.
- AbbVie and Calico announce a novel collaboration to accelerate the discovery, development and commercialization of new therapies. http://abbvie.mediaroom.com/2014–09–03-AbbVie-And-Calico-Announce-A-Novel-Collaboration-To-Accelerate-The-Discovery-Development-And-Commercialization-Of-New-Therapies.
- AbbVie and Calico announce a novel collaboration to accelerate the discovery, development and commercialization of new therapies. www.calicolabs.com/news/2014/09/03.
- Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy. www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/18_september_2014_oncology_html.
- Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy. www.curevac.com/fileadmin/curevac.de/media/Content/Newsroom/20140918_Press_release_Collaboration_CureVac_and_Boehringer_Ex-US.pdf.
- Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease. http://lilly.mediaroom.com/index.php?s=9042&item=137350.
- AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease. www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-and-lilly-announce-alliance.
- Novo Nordisk discontinues its activities within inflammatory disorders. www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=B7EFFD53–30F9-$DEA-8F71–88818CBE8F62.
- Baxter announces Baxalta as the name of the new global biopharmaceutical company. www.baxter.com/press_room/pres_re;leases/2014/09/09_10_14_baxalta.html.
- FDA approves Trulicity™ (dulaglutide), Lily's once-weekly therapy for adults with type 2 diabetes. http://lilly.mediaroom.com/index.php?s=9042&item=137354.
- Alimera Sciences provides details on FDA approval of Iluvien® as the first long-term treatment for diabetic macular edema. http://files.shareholder.com/downloads/ABEA-4IAIIR/3513768856x0x783732/c6f41d63–70e3–49b6-af37–947dd9298e6a/ALIM_News_2014_9_29_General_Releases.pdf.
- Allergan announces Orzudex® (dexamethasone 700 mcg intravitreal implant in applicator) now approved in the European Union for the treatment of diabetic macular edema. http://agn.client.shareholder.com/release detail;.cfm?ReleaseID=868483.
- Merck receives accelerated approval of Keytruda® (pembrolizumab), the first FDA-approved Anti-PD-1 therapy. http://mercknewsroom.com/print/node/698.
- Human anti-human PD-1 monoclonal antibody Opdivo® intravenous infusion 20mg/100mg launches in Japan for treatment of unresectable melanoma. www.ono.co.jp/eng/news/pdf/sm_cn140902.pdf.
- Takeda and Orexigen announce FDA approval of Contrave® (naltrexone HCl and buproprion HCl) extended-release tablets for chronic weight management. http://takeda.com/news/2014/20140911_6745.html.
- FDA approves Relistor® subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. http://news.salix.com/print/node 266.
- Uceris® (budenoside) 2mg rectal foam for the induction of remission of mild-to-moderate distal ulcerative colitis granted tentative approval by FDA. http://news.salix.com/print/node/260.
- European Commission grants Marketing Authorization for Gilead's Zydelig® (idelasib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma. www.gilead.com/news/press-releases/2014/9/european -commission-grants-marketing-authorization-for-gileads-zydelig-idelasib-for-the-treatment-of-chronic-lymphocytic-leukema-and-follicular-lymphoma.
- Lilly's basal insulin peglispro demonstrates HbA1c superiority agasint Lantus® in Phase III trials in patients with type 1 diabetes. http//lilly.mediaroom.com/index.php?s=9042&item=137346.
- Bausch + Lomb announces successful resut sform Phase 3 study of sub-micron loteprednol etabonate ophthalmic gel, 0.38%. http://ir.valeant.com/investor-relations/news-releases/news-release details/2014/Bausch +-Lomb-Announces-Successful-Results-from-Phase-3-Study of Sub-Micron-Loteprednol-Etabonate-Ophthalmic-Gel-038.
- Merck presents first Phase 3 data in Japanese patients for omarigliptin, an investigational once-weekly DPP-4 inhibitor for type 2 diabetes. www.mercknewsroom.com/print/node/707.
- Gilead's investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies. www.gilead.com/news/pres-releases/2014/9/gileads-investigational-tenofovir-alafenamide-tafbased-single-tablet-hiv-regimen-meets-48week-primary-objective-in-two-phase-3-studies.